Ipsen to discuss the future of Controlled Release Peptide Drug Delivery

SMi's Controlled Release conference, taking place on 18-19 April 2016 in London, will feature case studies from global pharmaceutical companies including GSK, Ipsen, Novo Nordisk, MedImmune, AstraZeneca, Lundbeck, Merck, UCB Pharma, Diurnal and more.
By: SMi Group
 
 
SMi's 13th annual Controlled Release conference
SMi's 13th annual Controlled Release conference
 
Spread the Word
Listed Under

Tags:
* Controlled Release
* Drug Delivery
* Pharma

Industry:
* Biotech

Location:
* London City - London, Greater - England

LONDON - Jan. 4, 2016 - PRLog -- Due to the excellent safety profile of polylactic-co-glycolic acid (PLGA) particles in humans, and their biodegradability, many studies have focused on the application of these particles as a controlled release vaccine delivery system. Antigenic peptides can be encapsulated into the surface of PLGA particles and the gradual release of loaded antigens from PLGA particles is necessary for the induction of efficient immunity. The co-delivery of antigens and immunostimulants (IS) with PLGA particles can prevent the systemic adverse effects of immunopotentiators and activate both dendritic cells (DCs) and natural killer (NKs) cells, consequently enhancing the therapeutic efficacy of antigen-loaded PLGA particles.
(Source: NCBI, 29 October 2015, ‘Peptide/protein vaccine delivery system based on PLGA particles’)

Against this backdrop, SMi is proud to announce that Ipsen’s Novel Drug Delivery Technologies Director, Andy Lewis, will be delivering a Keynote Address taking place on Day Two of SMi’s 13th annual Controlled Release conference at 09:10 titled ‘The future of controlled release peptide drug delivery’. His presentation will cover the following key points:
•        Review of routes of delivery of currently marketed peptide products
•        Novel peptide dosage forms currently in development
•        Future innovations in peptide delivery

The two-day programme will provide updates on the latest innovations to accelerate commercialisation and regulatory updates to ensure strict compliance with case studies provided by the MHRA, GlaxoSmithKline, Ipsen, Novo Nordisk, MedImmune, AstraZeneca, Lundbeck, Merck, Critical Pharmaceuticals, Kashiv Pharma, Diurnal and more.

Speaker Panel includes:
• David Elder, Due Diligence Director, GlaxoSmithKline
• Marion Westwood, Pharmaceutical Assessor, MHRA
• Andy Lewis, Director Novel Drug Delivery Technologies, Ipsen
• Sachin Mittal, Senior Principal Scientist, Merck
• Marianne Ashford, Principal Scientist Drug Targeting, AstraZeneca
• Sune Andersen, Principal Scientist, Novo Nordisk
• Mark Wilson, Director Platform Technology and Science, GlaxoSmithKline
• Saif Shubber, Formulation Scientist, MedImmune
• Rene Holm, Senior Director, Lundbeck

To view the full speaker line-up and conference programme, visit http://www.smi-online.co.uk/2016controlledrelease4.asp

PLUS – Don’t miss two interactive post-conference workshops taking place on 20th April 2016:

A: QbD/PAT Driven Controlled Release Design and Development | Led by Cristiana Campa, Head, Quality by Design Integration, GlaxoSmithKline and Jerome Mantanus, Senior Scientist QbD/PAT Drug Product Formulation, UCB Pharma

B: Exploring Controlled Release Drug Delivery Methods | Led by Rene Holm, Senior Director, Lundbeck; Clive Wilson, Professor of Pharmaceutics, University of Strathclyde; Ijeoma Uchegbu, Scientific Secretary CRS, Chair in Pharmaceutical Nanoscience, University Of London

Contact
SMi Group
vtrinh@smi-online.co.uk
+44 (0) 20 7827 6140
End
Email:***@smi-online.co.uk Email Verified
Tags:Controlled Release, Drug Delivery, Pharma
Industry:Biotech
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share